Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

323

Participants

Timeline

Start Date

September 23, 2013

Primary Completion Date

November 17, 2014

Study Completion Date

November 17, 2014

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

Faster-acting insulin aspart

Administrated subcutaneously (s.c., under the skin) at each main meal.

DRUG

basal insulin

Administrated subcutaneously (s.c., under the skin) once daily.

Trial Locations (58)

4000

Novo Nordisk Investigational Site, Kranj

8000

Novo Nordisk Investigational Site, Novo Mesto

8250

Novo Nordisk Investigational Site, Brežice

11229

Novo Nordisk Investigational Site, Brooklyn

19609

Novo Nordisk Investigational Site, Reading

20852

Novo Nordisk Investigational Site, Rockville

27203

Novo Nordisk Investigational Site, Asheboro

29651

Novo Nordisk Investigational Site, Greer

33028

Novo Nordisk Investigational Site, Pembroke Pines

33765

Novo Nordisk Investigational Site, Clearwater

35211

Novo Nordisk Investigational Site, Birmingham

35216

Novo Nordisk Investigational Site, Birmingham

44150

Novo Nordisk Investigational Site, Guadalajara

44650

Novo Nordisk Investigational Site, Guadalajara

45242

Novo Nordisk Investigational Site, Cincinnati

49009

Novo Nordisk Investigational Site, Kalamazoo

68144

Novo Nordisk Investigational Site, Omaha

70121

Novo Nordisk Investigational Site, New Orleans

72205

Novo Nordisk Investigational Site, Little Rock

73104

Novo Nordisk Investigational Site, Oklahoma City

76132

Novo Nordisk Investigational Site, Fort Worth

77478

Novo Nordisk Investigational Site, Sugar Land

78229

Novo Nordisk Investigational Site, San Antonio

80907

Novo Nordisk Investigational Site, Colorado Springs

80922

Novo Nordisk Investigational Site, Colorado Springs

84405

Novo Nordisk Investigational Site, Ogden

85381

Novo Nordisk Investigational Site, Peoria

89052

Novo Nordisk Investigational Site, Henderson

89120

Novo Nordisk Investigational Site, Las Vegas

92705

Novo Nordisk Investigational Site, Santa Ana

100097

Novo Nordisk Investigational Site, Ploieşti

110029

Novo Nordisk Investigational Site, New Dehli

160012

Novo Nordisk Investigational Site, Chandigarh

300125

Novo Nordisk Investigational Site, Timișoara

400007

Novo Nordisk Investigational Site, Mumbai

400058

Novo Nordisk Investigational Site, Mumbai

500034

Novo Nordisk Investigational Site, Hyderabad

500082

Novo Nordisk Investigational Site, Hyderabad

500269

Novo Nordisk Investigational Site, Brasov

530002

Novo Nordisk Investigational Site, Visakhapatnam

540142

Novo Nordisk Investigational Site, Târgu Mureş

641018

Novo Nordisk Investigational Site, Coimbatore

720237

Novo Nordisk Investigational Site, Suceava

91356-3551

Novo Nordisk Investigational Site, Tarzana

30094-5965

Novo Nordisk Investigational Site, Conyers

02118

Novo Nordisk Investigational Site, Boston

19335-2620

Novo Nordisk Investigational Site, Downingtown

29605-4254

Novo Nordisk Investigational Site, Greenville

38119-3821

Novo Nordisk Investigational Site, Memphis

77025-1669

Novo Nordisk Investigational Site, Houston

C1250AAN

Novo Nordisk Investigational Site, Buenos Aires

C1056ABJ

Novo Nordisk Investigational Site, Capital Federal

X5006IKK

Novo Nordisk Investigational Site, Córdoba

M5501ARP

Novo Nordisk Investigational Site, Godoy Cruz

B1642DCD

Novo Nordisk Investigational Site, San Isidro

560 017

Novo Nordisk Investigational Site, Bangalore

03300

Novo Nordisk Investigational Site, Mexico City

SI-6000

Novo Nordisk Investigational Site, Koper

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01850615 - Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter